[go: up one dir, main page]

AU2005294258A1 - Method for the treatment of polycystic kidney disease - Google Patents

Method for the treatment of polycystic kidney disease Download PDF

Info

Publication number
AU2005294258A1
AU2005294258A1 AU2005294258A AU2005294258A AU2005294258A1 AU 2005294258 A1 AU2005294258 A1 AU 2005294258A1 AU 2005294258 A AU2005294258 A AU 2005294258A AU 2005294258 A AU2005294258 A AU 2005294258A AU 2005294258 A1 AU2005294258 A1 AU 2005294258A1
Authority
AU
Australia
Prior art keywords
carbon atoms
alkyl
inhibitor
phenyl
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005294258A
Other languages
English (en)
Inventor
Philip Frost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2005294258A1 publication Critical patent/AU2005294258A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005294258A 2004-10-08 2005-10-07 Method for the treatment of polycystic kidney disease Abandoned AU2005294258A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61698104P 2004-10-08 2004-10-08
US60/616,981 2004-10-08
PCT/US2005/036122 WO2006042100A2 (fr) 2004-10-08 2005-10-07 Procede permettant le traitement d'une maladie polykystique des reins

Publications (1)

Publication Number Publication Date
AU2005294258A1 true AU2005294258A1 (en) 2006-04-20

Family

ID=36013658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005294258A Abandoned AU2005294258A1 (en) 2004-10-08 2005-10-07 Method for the treatment of polycystic kidney disease

Country Status (12)

Country Link
US (1) US20060079515A1 (fr)
EP (1) EP1796727A2 (fr)
JP (1) JP2008515913A (fr)
CN (1) CN101102757A (fr)
AR (1) AR052221A1 (fr)
AU (1) AU2005294258A1 (fr)
BR (1) BRPI0516533A (fr)
CA (1) CA2580864A1 (fr)
MX (1) MX2007004001A (fr)
PE (1) PE20060681A1 (fr)
TW (1) TW200616612A (fr)
WO (1) WO2006042100A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952459B (zh) 2005-02-03 2025-02-11 综合医院公司 治疗吉非替尼耐药性癌症的方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
KR20100016073A (ko) 2007-04-02 2010-02-12 인스티튜트 포 원월드 헬스 Ｃｆｔｒ 억제제 화합물 및 이의 용도
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009131951A2 (fr) * 2008-04-21 2009-10-29 Institute For Oneworld Health Composés, compositions et procédés comprenant des dérivés isoxazole
WO2009131952A1 (fr) * 2008-04-21 2009-10-29 Institute For Oneworld Health Composés, compositions et procédés comprenant des dérivés de thiazole
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
EP2278879B1 (fr) 2008-04-21 2016-06-15 PATH Drug Solutions Composés, compositions et traitements comprenant des dérivés d'oxydiazoles
WO2009131958A2 (fr) * 2008-04-21 2009-10-29 Institute For Oneworld Health Composés, compositions et procédés à base de dérivés de triazine
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
EP2341776A4 (fr) * 2008-09-19 2012-05-30 Inst Oneworld Health Composés, compositions et procédés comprenant des dérivés d'imidazole et de triazole
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
AU2011293315A1 (en) 2010-08-26 2013-03-14 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
WO2013019169A1 (fr) 2011-08-01 2013-02-07 Institute For Oneworld Health Promédicaments du phosphate
EP2956138B1 (fr) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Composés thérapeutiques et utilisations de ceux-ci
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
EP3509421A4 (fr) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (fr) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2357110A1 (fr) * 2001-04-11 2002-10-11 American Cyanamid Company Methode de traitement de la polykystose renale
AU2002359489B2 (en) * 2001-11-27 2008-10-30 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and Her2 kinases

Also Published As

Publication number Publication date
MX2007004001A (es) 2007-05-11
CA2580864A1 (fr) 2006-04-20
CN101102757A (zh) 2008-01-09
EP1796727A2 (fr) 2007-06-20
PE20060681A1 (es) 2006-08-28
WO2006042100A3 (fr) 2007-06-07
BRPI0516533A (pt) 2008-09-09
TW200616612A (en) 2006-06-01
AR052221A1 (es) 2007-03-07
JP2008515913A (ja) 2008-05-15
US20060079515A1 (en) 2006-04-13
WO2006042100A2 (fr) 2006-04-20

Similar Documents

Publication Publication Date Title
AU2005294258A1 (en) Method for the treatment of polycystic kidney disease
JP6162687B2 (ja) 新規のビスアミノキノリン化合物、それから調製した医薬組成物、及びそれらの使用
RU2309150C2 (ru) 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
EP1379507B1 (fr) Urees heteroaryles contenant des hetero-atomes d'azote comme inhibiteurs de kinase p38
KR20020018201A (ko) 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물
KR102011641B1 (ko) 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
MXPA02008836A (es) Uso de cianoquinolinas para tratar o inhibir los polipos colonicos.
CN108366992A (zh) 蛋白水解靶向嵌合体化合物及其制备和应用方法
JP2002519379A (ja) 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
CA1330660C (fr) Derives de l'acide kynurenique utiles pour le traitement de desordres neurodegeneratifs
CA2122841A1 (fr) Derives quinolone
CN105777464A (zh) 异羟肟酸衍生物及其制备方法和应用
JP4377454B2 (ja) Ｎｋ３拮抗物質としてのキノリン誘導体の塩
JP2575569B2 (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
KR20110021946A (ko) 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도
KR19990067528A (ko) 카인산 신경 세포 독성 억제제 및 피리도티아진 유도체
RU2294198C2 (ru) Производные арил(или гетероарил)азолилкарбинола для лечения респираторных заболеваний
US5476858A (en) Use of carbostyril to increase somatostatin or for inhibiting decrease of somatostatin to treat diseases related thereto
RU95109440A (ru) Производные 4-хинолинила, обладающие антигеликобактериальной активностью, способ их получения, фармацевтическая композиция, их содержащая, и способ ее получения
AU2004222642A1 (en) Phenylcarboxyl acid amides and IK channel inhibitors combination and the use thereof for treating atrial arrhythmia
CZ378597A3 (cs) Použití derivátů pyrrolidinu k léčení alkoholismu
JP7495758B2 (ja) マクロライド化合物及びその慢性呼吸器疾患の治療用途
JP2004300147A (ja) 受容体拮抗剤
CN101355944A (zh) 治疗肺动脉高血压的二芳基脲
JP2000273042A (ja) 医 薬

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application